PTN studies managed via the POPS paradigm seek to determine the appropriate dosing of understudied drugs in children by using samples collected as part of regular care (for example, blood draws). The data collected provides valuable pharmacokinetic and dosing information for drugs in different pediatric age groups and special pediatric populations (such as obese children).
Dr. Ram Yogev, POPS Investigator at Lurie Children’s Hospital of Chicago, explains, “The current empirically-based dose selection for pediatric patients can be improved by applying evidence-based dosing strategies. POPS studies provide important information about how best to dose medications in children and adolescents, and support dosing strategies that provide the best chance for any given drug to demonstrate both efficacy and acceptable tolerability.”
Since its inception, POPS has investigated 48 understudied drugs with 19 currently enrolling. POPS has a total of 31 active sites, and in March, two UK sites joined the ranks, Southampton General Hospital and Alder Hey Children’s Hospital. As of June 1, POPS sites enrolled 1904 participants of the targeted 3000.